A Phase 2 interventional study of Nab-paclitaxel in Nasopharyngeal Carcinoma, sponsored by Fuzhou General Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-11.
Sponsored by Fuzhou General Hospital · Phase 2, Interventional, and Treatment
Nasopharyngeal carcinoma (NPC) is a malignant tumor that originates in nasopharyngeal epithelial cells. It is common in southern China and Southeast Asia, but the incidence rate is low in most parts of the world. According to the World Health Organization survey, 80% of nasopharyngeal carcinomas occur in China, with high incidence in southern China, as high as 30-50/100,000, such as Guangdong, Guangxi, Hunan, and Fujian. In 2015, Chinese cancer statistics showed that there were about 60,600 new cases of nasopharyngeal carcinoma in China, and the number of deaths was about 34,100. Radiation therapy is the main treatment for nasopharyngeal carcinoma. Early stage I and IIa achieved a 5-year survival rate (OS) of 90% and 84%, respectively . However, the treatment outcomes of most patients with locally advanced nasopharyngeal carcinoma are not ideal.
824 studies on the registry are indexed under Nasopharyngeal Carcinoma; 281 are open to participants now.
This study's planned enrollment of 92 is close to the median of 84 across 674 interventional studies indexed under Nasopharyngeal Carcinoma.
Browse Nasopharyngeal Carcinoma studies →Fuzhou General Hospital is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
induction chemotherapy by nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
Drug: Nab-paclitaxel
induction chemotherapy by paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
Drug: Nab-paclitaxel
induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
Also known as: Paclitaxel for Injection (Albumin Bound)
Objective response rate (ORR)
To be determined by measurement of target lesions according to RECIST criteria
Time frame: 3 years
Progression-Free Survival(PFS)
From the date of enrollment to the date of either locally, regionally or distant failure or last follow-up
Time frame: 3 years
Overall survival（OS）
From the date of enrollment to the date of death is observed or to last follow-up visit
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel
Fuzhou General Hospital